Brief: HBM Holdings Gets IND Approval For Anti-TSLP Fully Human Monoclonal Antibody In Asthma From China's NMPA
21/02/2022 10:49
Feb 21 (Reuters) - Hbm Holdings Ltd 2142.HK :
* GOT IND APPROVAL FOR ANTI-TSLP FULLY HUMAN MONOCLONAL
ANTIBODY
IN ASTHMA FROM CHINA'S NMPA
Source text for Eikon: ID:
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study